Why the world needs cults

My professional life has been spent tracing how institutions bend, fracture, or adapt when imported into soil they were never designed for. I have spent six years watching multi-ethnic states in Southeast Asia attempt to transplant Western democratic mechanisms into societies governed by patronage networks, religious hierarchies, and deep historical memory. The result is rarely a clean replication. It is a messy negotiation between formal rules and informal power.

 

So when I turn to the question of gene editing, I am not doing so as a geneticist. I am doing so as a student of governance. The CRISPR revolution presents a remarkably similar governance problem to the ones I study in Jakarta, Bangkok, and Manila. You have a powerful tool, developed in one context—high-tech Western laboratories with specific assumptions about individual autonomy and market access—and you are about to release it into a world of wildly uneven regulatory capacity, vast economic inequality, and competing moral frameworks. The question is not whether the science works. The question is whether our institutional architecture can survive the shock.
 

The Governance Gap in the CRISPR Era

The scientific achievement is not in dispute. Jennifer Doudna and Emmanuelle Charpentier took a bacterial defense mechanism—a system that bacteria have been using for a billion years to chop up invading viruses—and turned it into a programmable tool for cutting human DNA. The technical elegance is breathtaking. You take a mugshot of a virus, store it in the bacterial code, and deploy a pair of molecular scissors guided by RNA to cut the target. That is a stunning feat of biological engineering.
 

But my interest lies elsewhere. The moment Doudna helped invent this technology, she had a nightmare. In it, someone wanted to learn how to use the tool. She walked into the room, and it was Hitler. That nightmare is not a scientific problem. It is a political problem. It is the fear that a technology designed for healing can be captured by forces designed for domination.
 

The governance gap is this: the speed of technological development has far outpaced the speed of institutional adaptation. In the countries I study, this gap is the source of chronic instability. When a new economic policy or constitutional reform arrives faster than the courts, legislatures, and civic norms can absorb it, the result is not orderly progress. The result is elite capture, populist backlash, or violent fragmentation.
 

We are now facing the same dynamic globally. The first human applications of CRISPR are already here. Victoria Gray, a patient with sickle cell disease, had her stem cells edited and reinserted into her body. She is now producing healthy blood cells. That is a miracle. But the same technology that can correct a point mutation in hemoglobin can, in theory, be used to select for height, eye color, or cognitive traits. The line between therapy and enhancement is not a scientific line. It is a regulatory line. And regulatory lines require institutions that can draw them, enforce them, and adapt them over time.
 

Parameter Disassembly: What Are We Actually Regulating?

In my work on democratic transition, I have learned to distrust broad categories. "Democracy" is too vague a term to analyze. You must disassemble it into parameters: electoral competitiveness, judicial independence, civil society density, military autonomy, media pluralism. Only then can you see which specific parameters are failing and why.
 

I apply the same method to gene editing. The term "CRISPR" obscures more than it reveals. We need to disassemble the regulatory challenge into distinct parameters.
 

Somatic versus germline editing. Somatic editing changes cells in a single patient. The changes die with that patient. Germline editing changes sperm, eggs, or embryos. The changes are inheritable. They enter the human gene pool and cascade across generations. These are fundamentally different governance problems. The first is essentially a medical regulation issue, analogous to approving a new drug. The second is a species-level intervention, analogous to nothing in previous human history.
 

Therapy versus enhancement. Treating sickle cell disease, cystic fibrosis, Huntington's, or Tay-Sachs has a clear medical rationale. The patient is suffering. The intervention restores normal function. Enhancement is different. It does not treat disease. It optimizes for traits that a particular society values. That is a eugenic logic, whether we admit it or not. And the moment you allow a market in genetic enhancement, you create a biological aristocracy.
 

State action versus private markets. The nightmare of Hitler is a nightmare about state coercion. But in many of the countries I study, the more immediate threat is not the state. It is the unregulated market. Clinics in Southeast Asia, South Asia, and parts of the Middle East already offer unproven stem cell therapies to medical tourists. The regulatory arbitrage is already happening. A wealthy couple in Bangkok can access services that a middle-class family in Chicago cannot. That is not a state policy. That is a market failure.
 

National regulation versus international fragmentation. Every country I have studied has a different capacity to regulate. Singapore has robust regulatory bodies. Cambodia does not. Indonesia is somewhere in between. If one jurisdiction bans germline editing and another permits it, the ban is only as strong as the weakest passport. We saw this with surrogacy. We saw it with clinical trials. We will see it with gene editing.
 

Disassembling the problem this way changes the conversation. It moves us away from vague pronouncements about "playing God" and toward specific institutional design questions. Who has the authority to approve a germline edit? What evidence standard is required? What penalties apply for noncompliance? How do we prevent regulatory havens from emerging?
 

Root Cause Tracing: Why Institutions Lag Behind

In my research on Southeast Asia, I have often asked: why do institutions fail? The answer is rarely that people are evil or incompetent. The answer is that institutions are designed for one set of problems and then confronted with a different set. The mismatch is the source of failure.
 

The same is true for gene editing governance. Our current institutions were designed for a world where genetic modification was slow, expensive, and largely limited to agriculture. The regulatory frameworks that govern gene therapy were built in the 1990s and early 2000s, before CRISPR made the process cheap, fast, and accessible to any moderately equipped laboratory.
 

The root cause of the governance gap is what I call institutional lag. Institutions change slowly. Technologies change quickly. The lag is not a bug. It is a feature of any system that values stability and due process. But when the lag becomes too large, the system becomes illegitimate. People lose faith that the institutions can protect them. And when people lose faith, they turn to informal mechanisms—black markets, private networks, charismatic leaders—that are even harder to regulate.
 

There is a second root cause: regulatory capture by entrepreneurial scientists. This is not a conspiracy theory. It is a well-documented phenomenon in my field. When a new technology emerges, the people who understand it best are the people who develop it. Regulators must rely on these experts for technical guidance. But those same experts have a financial and reputational stake in the technology's success. The result is a regulatory system that is deeply dependent on the very community it is supposed to oversee.
 

I saw this pattern in the financial sector during the Asian Financial Crisis of 1997. Regulators relied on the same bankers and economists who had created the fragile system. They did not see the crisis coming because they were inside the system. The same dynamic applies to gene editing. The scientists who developed CRISPR are brilliant. They are also human. They have incentives. They have blind spots. And they have a deep emotional investment in the technology they created.
 

A third root cause is the absence of a clear sovereignty principle. In traditional governance, the state has a monopoly on violence and a defined territorial jurisdiction. Gene editing disrupts both. A scientist in one country can edit an embryo that will be implanted in a second country and born in a third. Which country's laws apply? The answer is unclear. And in the absence of clear jurisdiction, we get either paralysis or a race to the bottom.
 

The Adaptive Dilemma: Lessons from Southeast Asia

I want to be careful here. I am not arguing that Southeast Asia is a model for gene editing governance. It is not. But the region does offer a useful laboratory for understanding how institutions adapt—or fail to adapt—when confronted with disruptive change.
 

Consider the experience of multi-ethnic states in Southeast Asia with democratic transition. The Western model assumed that competitive elections would produce legitimate governments. In many cases, they did not. They produced ethnic polarization, vote-buying, and the entrenchment of oligarchic networks. The institutions were not wrong. They were incomplete. They lacked the supporting infrastructure—civic education, independent media, judicial capacity—that made elections meaningful.
 

The lesson for gene editing is straightforward. You cannot simply announce a regulatory framework and expect it to work. You need the supporting infrastructure. You need scientists who are trained in ethics as well as technique. You need independent review boards with real authority. You need public education so that citizens can participate in the conversation. You need international coordination so that the rules are not undermined by a single bad actor.
 

The second lesson is about the danger of elite capture. In my region, well-intentioned reforms are often captured by the very elites they were meant to constrain. Land reform programs benefit large landholders. Anti-corruption commissions target political rivals. The same risk applies to gene editing. If we allow the technology to be developed and deployed by a small group of wealthy institutions and individuals, the benefits will flow to them. The risks will be socialized. That is not a conspiracy. That is how power works.
 

The third lesson is about the importance of informal norms. In many Southeast Asian societies, formal law is weak, but informal norms—religious teachings, community pressure, family obligations—are strong. These norms can be a source of stability or a source of resistance. The same will be true for gene editing. The formal regulatory framework matters. But so do the informal norms of the scientific community, the medical profession, and the broader public. If those norms say that inheritable editing is a line not to be crossed, the formal rules will be more effective. If the norms are ambiguous or permissive, the formal rules will be tested.
 

The Ethical Architecture: What Would a Reasonable Framework Look Like?

I should be explicit about my own position. I am not a bioethicist. My own work leans toward a precautionary approach, not because I am hostile to innovation, but because I have seen too many cases where rapid change overwhelmed institutional capacity and produced suffering. The people who pay for institutional failure are rarely the people who benefit from technological progress.
 

A reasonable framework would, in my view, do several things.
 

Draw a bright line at germline editing. Somatic editing should be treated as a medical intervention, regulated like other gene therapies. Germline editing is different. It affects future generations who cannot consent. It alters the human gene pool. It should be treated as a species-level intervention, subject to a much higher level of scrutiny and a much slower approval process.
 

Focus on therapy, not enhancement. The case for treating sickle cell, Huntington's, and other devastating conditions is strong. The case for enhancing height or cognitive ability is weak, and the risks of a genetic supermarket are real. If people could buy better genes for their children, we would harm the human species. That is not a theological claim. It is a political economy claim about how markets produce inequality.
 

Build international coordination before the crisis hits. Waiting for a scandal to emerge is a recipe for a bad response. We need mechanisms for sharing information, harmonizing standards, and imposing consequences on jurisdictions that flout the rules. This will not be easy. International coordination never is. But the alternative—a fragmented system where the weakest jurisdiction sets the standard—is worse.
 

Invest in public education and deliberation. The scientific community cannot make these decisions alone. Nor can politicians. The public has a stake in the outcome, and the public's values should matter. This does not mean that every citizen needs to understand the molecular biology of CRISPR. But it does mean that citizens should understand the basic stakes and have a voice in the decisions that will shape their children's future.
 

A Specific Case Worth Watching

I have been asked to ground this analysis in at least one specific case, and I want to avoid the most obvious examples. Victoria Gray's sickle cell treatment is well known. The He Jiankui case—the Chinese scientist who edited embryos to confer HIV resistance and was jailed for it—is also widely cited. Both are important. But I want to focus on something slightly different.
 

The case that concerns me most is not a single event. It is a pattern emerging in the medical tourism industry. In my region, clinics are already marketing unproven gene-based therapies to international patients. These clinics operate in regulatory gray zones. They combine the language of scientific progress with the machinery of hospitality and marketing. They target wealthy patients who are desperate for cures that conventional medicine cannot offer. They promise more than they can deliver. And they are almost impossible to regulate because they operate across borders and use online platforms to reach patients.
 

This is not a hypothetical. It is happening now. And it demonstrates the core problem with the governance gap. The technology is moving faster than the institutions. The result is not a dystopian future of designer babies. It is a present-day reality of unregulated clinics, unverified claims, and vulnerable patients. The dystopian future is a distraction from the messy, exploitative present.
 

Final Weighted Priorities

I do not believe in presenting a neat list of recommendations. The world does not work that way. But if I were forced to identify the highest priorities, I would say this.
 

The single most important step is to build institutional capacity before the technology becomes too cheap and too widespread to control. That means investing in regulatory bodies, training scientists in ethics, and creating international coordination mechanisms now, while the window is still open. The second priority is to draw a clear line at germline editing, not because I am certain that inheritable changes are always wrong, but because once that door is opened, it cannot be closed. The third priority is to address the inequality problem directly. The risk is not that gene editing will be used by everyone. The risk is that it will be used by the few, and the gap between the few and the many will widen.
 

The scientific method has always been about open inquiry, about approaching things with an open mind, about saying, "Show me the evidence." That is what I wish people would think about. It is not just about science. It is about the scientific method. Which means you are open to changing your mind. The same should be true for our governance institutions. They must be open to evidence, willing to adapt, and humble about their own limitations.
 

I have spent my career studying what happens when institutions are too rigid to adapt. The result is rarely violence in the streets. It is usually something quieter: the slow erosion of trust, the gradual capture of public goods by private interests, the widening gap between those who understand the system and those who are subject to it. Gene editing will test our institutions in exactly this way. The question is whether we are capable of learning from the failures of the past before we repeat them in a new and more permanent form.
 

Reference Block
 

Source Reference Link: https://www.ted.com/talks/walter_isaacson_how_crispr_gene_editing_will_change_the_world/transcript
 

Link Brief: Walter Isaacson discusses Jennifer Doudna's discovery of CRISPR as a reprogrammable gene-editing tool, the scientific journey from RNA research to bacterial immune systems, and the ethical perils of inheritable human genome modification. The transcript grounds this article's analysis of the governance gap between technological speed and institutional adaptation capacity.
 

Content Disclaimer
 

This article is for general reference only and does not constitute professional R&D guidance, production process advice or quality certification. All material performance data has specific test premises; readers should verify parameters against actual equipment and working conditions.